Furthermore, we discuss the clinical trials and therapeutic potential of regulatory cell-based therapies and lower-dose IL-2 therapy to restore immune tolerance by Tregs manipulation in patients with SLE. The gene discussed is IL2; the disease is systemic lupus erythematosus.